Skip to content

Study · Randomized controlled trial · 1991

3 results

Bone densitometric and histomorphometric responses to sequential human parathyroid hormone (1-38) and salmon calcitonin in osteoporotic patients.

Hodsman AB, Steer BM, Fraher LJ, Drost DJ

Bone and mineral1 Jul 1991Cited by 61 (Europe PMC)

PMID1868270 (opens in a new tab)DOI10.1016/0169-6009(91)90103-7 (opens in a new tab)PepBankPUB-01868270
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In osteoporotic patients receiving hPTH (1-38), the overall change in serum alkaline phosphatase across time was significantly less with added salmon calcitonin than without (P less than 0.04), although it still increased in the calcitonin group.

    In plain wordsIn osteoporotic patients given hPTH, alkaline phosphatase rose less with added salmon calcitonin than without, though it still rose.

    Peptide
    Calcitonin-salmon
    Outcome
    DecreaseSerum alkaline phosphatase
    Study

    n: not reported in source

    Comparator
    hPTH (1-38) without salmon calcitonin
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Average 79 units per day · 56 days after each activation phase, over two cyclesAs given in this study (human).

    Measurements

    Alkaline phosphatase change from baseline
    15%
    Group 2 (hPTH plus salmon calcitonin), first cycle, reported as 15 +/- 15%
    Alkaline phosphatase change from baseline
    8%
    Group 2 (hPTH plus salmon calcitonin), second cycle, reported as 8 +/- 6%

    Source sentences

    Summary
    The overall changes in serum Alk. P'ase across time were significantly less (P less than 0.04) in Group 2; however this parameter also increased by 15 +/- 15% during the first cycle and 8 +/- 6% during the second cycle.
    3 context sentences
    Summary · context
    In this report an ADFR protocol was developed in which all patients received synthetic hPTH (1-38) for the first 14 days of a 100 day cycle.
    Summary · context
    Half the patients received no other therapy (Group 1), but were followed closely with repeated vertebral bone mineral measurements over two full cycles.
    Summary · context
    The remaining patients (Group 2) were randomly allocated to receive salmon calcitonin, at an average dose of 79 units per day for a 56 day depressor period immediately following each phase of activation.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In osteoporotic patients receiving hPTH (1-38), bone mineral measurements showed no significant changes with added salmon calcitonin (Group 2), and the differences between the two groups were not significant.

    In plain wordsIn osteoporotic patients given hPTH, adding salmon calcitonin did not significantly change bone mineral measurements compared with no calcitonin.

    Peptide
    Calcitonin-salmon
    Outcome
    No significant changeBone mineral measurements
    Study

    n: not reported in source

    Comparator
    hPTH (1-38) without salmon calcitonin
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Average 79 units per day · 56 days after each activation phase, over two cyclesAs given in this study (human).

    Source sentences

    Summary
    There were no significant changes in bone mineral measurements in Group 2, but the differences between the two groups were not significant.
    3 context sentences
    Summary · context
    In this report an ADFR protocol was developed in which all patients received synthetic hPTH (1-38) for the first 14 days of a 100 day cycle.
    Summary · context
    Half the patients received no other therapy (Group 1), but were followed closely with repeated vertebral bone mineral measurements over two full cycles.
    Summary · context
    The remaining patients (Group 2) were randomly allocated to receive salmon calcitonin, at an average dose of 79 units per day for a 56 day depressor period immediately following each phase of activation.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In osteoporotic patients receiving hPTH (1-38), individual bone formation rates did not differ significantly with added salmon calcitonin versus no calcitonin.

    In plain wordsIn osteoporotic patients receiving hPTH, bone formation rates did not differ significantly with added salmon calcitonin compared with no calcitonin.

    Peptide
    Calcitonin-salmon
    Outcome
    No significant changeIndividual bone formation rates
    Study

    n: not reported in source

    Comparator
    hPTH (1-38) without salmon calcitonin
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Average 79 units per day · 56 days after each activation phase, over two cyclesAs given in this study (human).

    Source sentences

    Summary
    Individual bone formation rates (surface referent) were not significantly different between the two groups;
    3 context sentences
    Summary · context
    In this report an ADFR protocol was developed in which all patients received synthetic hPTH (1-38) for the first 14 days of a 100 day cycle.
    Summary · context
    Half the patients received no other therapy (Group 1), but were followed closely with repeated vertebral bone mineral measurements over two full cycles.
    Summary · context
    The remaining patients (Group 2) were randomly allocated to receive salmon calcitonin, at an average dose of 79 units per day for a 56 day depressor period immediately following each phase of activation.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.